New drug combo aims to tackle Hard-to-Treat myeloma
Disease control
Recruiting now
This study tests a combination of two drugs, mezigdomide and elranatamab, in 75 people with relapsed or refractory multiple myeloma (a blood cancer that has come back or stopped responding to treatment). The goal is to see how well the combination works and how safe it is. Partic…
Phase: PHASE1, PHASE2 • Sponsor: YOUNGIL KOH • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC